ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr PharmaFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (
NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Levi & Korsinsky Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ATYRSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Levi & Korsinsky Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ATYRNEW YORK - November 19, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. (
NASDAQ: ATYR) of a class action securities lawsuit.
Levi & Korsinsky Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ATYRSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Levi & Korsinsky Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ATYRNEW YORK - November 18, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. (
NASDAQ: ATYR) of a class action securities lawsuit.
Bragar Eagel & Squire, P.C. Reminds Stockholders of aTyr, Marex, Cepton, and MoonLake to Contact the Firm About their Rights Before Upcoming DeadlinesNEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of aTyr Pharma, Inc. (
NASDAQ:ATYR), Marex Group PLC (
NASDAQ:MRX), Cepton, Inc. (
NASDAQ:CPTN), and MoonLake Immunotherapeutics (
NASDAQ:MLTX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Nov. 17, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (
NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
aTyr Pharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ATYRSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
aTyr Pharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ATYRNEW YORK - November 17, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. (
NASDAQ: ATYR) of a class action securities lawsuit.
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (
NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Contact Levi & Korsinsky by December 8, 2025 Deadline to Join Class Action Against aTyr Pharma, Inc. (ATYR)Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Contact Levi & Korsinsky by December 8, 2025 Deadline to Join Class Action Against aTyr Pharma, Inc. (ATYR)NEW YORK - November 12, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. (
NASDAQ: ATYR) of a class action securities lawsuit.
Bragar Eagel & Squire, P.C. Reminds Investors of aTyr, Marex, Cepton, and MoonLake to Contact the Firm About their Rights in Filed Class Action LawsuitsNEW YORK, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of aTyr Pharma, Inc. (
NASDAQ:ATYR), Marex Group PLC (
NASDAQ:MRX), Cepton, Inc. (
NASDAQ:CPTN), and MoonLake Immunotherapeutics (
NASDAQ:MLTX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (
NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Class Action Filed Against aTyr Pharma, Inc. (ATYR) Seeking Recovery for Investors - Contact Levi & KorsinskySearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Class Action Filed Against aTyr Pharma, Inc. (ATYR) Seeking Recovery for Investors - Contact Levi & KorsinskyNEW YORK - November 11, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. (
NASDAQ: ATYR) of a class action securities lawsuit.
